About Remel
Remel is a company based in Lenexa (United States) founded in 1973 was acquired by Thermal Scientific in April 1997. Remel operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Lenexa, United States
- SectorsHealthcare
- Website remel.com
- Acquired by Thermal Scientific (Apr 1997)
- Investors
- Acquired byThermal Scientific
(Apr 1997)
Investors in Remel
Remel has secured backing from 1 investor. Prominent investors backing the company include Thermal Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Thermal Scientific is engaged in distributing laboratory supplies and equipment. | 1962 | thermalscientific.com | Mansfield, United States |
Investor details for Remel
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Remel
2 dated milestones of Remel across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Remel is founded.
- Exit Acquired by Thermal Scientific.
Competitors of Remel
Remel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Remel
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Remel
The website of Remel (remel.com) receives about 5.6K visits a month.
- Monthly visits5.6K
▼ 5.3% vs previous month
Websites whose visitors overlap most with Remel. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thermoscientific.com | thermoscientific.com | 100% | – | – | – |
| cepheid.com | 92% | 117.9K | #496,659 | View details | |
| bd.com | 73% | 1.2M | #57,463 | View details | |
| dako.com | 60% | 1.6K | #11,422,431 | View details | |
matrixtechcorp.com | matrixtechcorp.com | 26% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Remel
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Remel
Complete news archive for Remel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Remel
10 companies that operate in the same segment as Remel (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Remel
Remel was founded in 1973.
Remel is headquartered in Lenexa, United States. It is registered at Lenexa, Kansas, United States.
Remel manufactures and markets a wide range of microbiology products. Its product line includes prepared and dehydrated culture media products, collection and transport systems, diagnostic and direct specimen tests, quality control systems, and laboratory supplies. The company also offers clinical products in the areas of microbiology, parasitology, immunology, serology, mycology, virology, and hematology; and industrial products in the areas of food and beverage, pharmaceutical and biotech, personal care products, medical devicediagnostics, environmental, and water testing.
Remel's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Remel has 1 investor. Key investors include Thermal Scientific.
Yes. Remel was acquired by Thermal Scientific in April 1997.